ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma

May 17, 2018 – In updated guidelines exploring the role of bone-modifying agents, the American Society of Clinical Oncology (ASCO) has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma. The previous guidelines recommended bone-modifying agents only for patients with lytic disease, said Kenneth C. Anderson, MD, program director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma … (leggi tutto)